Developing therapeutic platforms from new biological insight

ClearMTB Therapeutics is a Danish research-driven biotechnology company building new therapeutic platforms across systems biology, cell engineering, microbiome research and neuromodulation.

Odense & Assens, Fyn — Denmark · Founded 2024
Our model

Platform-based research

We work with a platform-based research model where new biological mechanisms are formalized as therapeutic frameworks. These frameworks can subsequently be translated into concrete treatment programs or partnerships with larger biotech and pharmaceutical companies.

Approach

Four domains of innovation

Our research spans multiple disciplines, each representing a unique opportunity to develop the next generation of therapeutics.

01

Systems biology

Understanding complex biological networks and their interactions to identify novel therapeutic targets and develop more effective intervention strategies.

02

Cell engineering

Advanced design and optimization of cellular therapeutic platforms with a focus on long-term stability, function and clinical translatability.

03

Microbiome research

Developing engineered microbiome-based therapeutics that can coordinately modulate multiple biological pathways in the gastrointestinal system.

04

Neuromodulation

Precision neural stimulation frameworks using real-time brain activity monitoring to deliver therapy at optimal moments of plasticity.

05

Novel drug modalities

Exploring new therapeutic strategies targeting the physical material properties of biomolecular condensates to restore cellular function.

06

Translational focus

Every platform is designed from the outset with translation in mind — from mechanistic insight to clinically relevant research programs ready for partnership.

Pipeline

Our research platforms

Four parallel therapeutic platforms, each based on unique biological insights and designed for translational development.

ProgramDescription
EpiState-Lock
Cell Engineering
Computational framework for epigenetic stability in engineered cells. Understanding how trajectory history determines cellular stability and function.
GutSync Platform
Engineered Microbiome
Engineered biotherapeutic consortium. Multiple genetically optimized strains in a single capsule to restore gastrointestinal homeostasis.
PINNACLE
Neuroplasticity Framework
Targeted neural circuit reorganization using EEG-based real-time analysis and closed-loop stimulation during optimal plasticity states.
Condensate Rheology Modulators
Novel Drug Modality
Modulating physical material properties of protein condensates to restore gene regulation and cellular function in disease processes.
New biological mechanisms, formalized as therapeutic frameworks, ready for translation
— ClearMTB Therapeutics research philosophy
Platform details

Deeper into our science

Cell Engineering

EpiState-Lock

A theoretical and computational framework for understanding epigenetic stability in engineered cells. The platform builds on the idea that cellular stability depends not only on the end state, but also on the epigenetic path the cell has taken to reach it.

The framework introduces several key concepts for evaluating and designing stable cellular therapeutics:

Epigenetic Momentum Score — quantifying trajectory-dependent stability
Optimal Trajectory Design — engineering the path, not just the destination
Trajectory Stability Index — predicting long-term functional persistence
Engineered Microbiome

GutSync Platform

A platform based on engineered microbiome therapeutics. The central concept is an Engineered Biotherapeutic Consortium, where multiple genetically optimized bacterial strains are delivered in a single capsule.

Together, these strains produce bioactive molecules that can influence multiple biological signaling pathways in the gastrointestinal system. The goal is to restore gastrointestinal homeostasis through coordinated modulation of the microbiome, immune response and metabolic signaling pathways.

Neuroplasticity Framework

PINNACLE

A neuroplasticity framework designed for targeted reorganization of neural circuits. The system uses EEG-based measurement, real-time analysis and closed-loop stimulation.

Stimulation is delivered only in moments when the brain is in optimal learning and plasticity states. The goal is more precise and effective neural modulation — moving beyond broad stimulation toward temporally targeted intervention.

Novel Drug Modality

Condensate Rheology Modulators

A new therapeutic strategy targeting biomolecular condensates in cells. Instead of blocking receptors or enzymes, this approach changes the physical material properties of protein condensates involved in disease processes.

By modulating viscosity or dynamics in these structures, it may be possible to restore normal gene regulation and cellular function — representing an entirely new modality for therapeutic intervention.

Team

Research-focused leadership

A small, dedicated team driving ClearMTB's therapeutic platforms forward from Fyn, Denmark.

MM

Mathias Madsen

CEO & Founder

NH

Noah Hansen

VP Communications & Outreach

NL

Noah Laursen

Research Director

VP

Victor Peter

Research Associate

Collaboration

Open for partnerships

We seek collaboration with organizations that share our ambition to develop the next generation of therapeutic platforms.

Academic institutions

Joint research projects and knowledge exchange within our platform domains. We actively seek academic partnerships to strengthen the scientific foundation of our frameworks.

Biotech companies

Strategic partnerships for development and validation of new therapeutic frameworks. We are designed to work with partners who can bring these platforms through clinical development.

Translational organizations

Translating research findings into clinically relevant programs and treatments. We bridge the gap between biological insight and therapeutic application.

Contact

Get in touch

Location

Odense & Assens
Fyn, Denmark

Interested in working with us?

We are always open to discuss collaboration opportunities with research institutions, biotech companies and translational organizations. We look forward to hearing from you.

Send us an email